ZURICH (Reuters) – Switzerland’s Novartis plans to get full control of eye care group Alcon for a total $39.3 billion, to diversify away from prescription drugs, after agreeing to acquire a majority stake from Nestle.

Here is the original:
Novartis plans to buy rest of Alcon for $39 billion